Company profile: CorFlow Therapeutics
1.1 - Company Overview
Company description
- Provider of proprietary medtech technologies to diagnose and treat microvascular obstructions (MVO) in heart attack patients. Offers the CoFI System for post-PCI coronary microcirculation assessment and controlled infusion of diagnostic/therapeutic agents, the CoFI Console acting as an infusion pump and displaying physiological parameters, an infusion-occlusion CoFI Catheter, and a single-use CoFI Cassette.
Products and services
- CoFI System: Post-PCI device that assesses coronary microcirculation to detect MVO and performs controlled infusion of diagnostic and therapeutic agents directly into the microvasculature
- CoFI Catheter: 6 Fr-compatible infusion‑occlusion balloon catheter that interfaces with a 0.014” pressure wire to deliver axial infusion precisely during temporary vessel occlusion
- CoFI Console: Pump-integrated capital equipment that drives infusates at controlled flow rates and displays physiological parameters to support coronary microvascular obstruction detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CorFlow Therapeutics
Hemostemix
HQ: Canada
Website
- Description: Provider of autologous cell therapies derived from a patient's own blood, including ACP-01 to regenerate blood flow and tissue for ischemic conditions such as critical limb ischemia, peripheral arterial disease, angina, and ischemic cardiomyopathy, and NCP-01, a neuronal cell precursor therapy aimed at treating central and peripheral nervous system conditions including neuropathic pain, spinal cord injuries, and stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemostemix company profile →
Cardiokine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development for the prevention and treatment of cardiovascular diseases, including lixivaptan, an orally active vasopressin receptor antagonist for congestive heart failure patients with hyponatremia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardiokine company profile →
Positron
HQ: United States
Website
- Description: Provider of full nuclear cardiology solutions as a research and development company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Positron company profile →
Celera
HQ: United States
Website
- Description: Provider of molecular diagnostic products and services that leverage knowledge of human variability to personalize disease management, enabling hospitals and clinical laboratories to detect, characterize, monitor, and select treatment for disease, including genotyping for infections diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celera company profile →
LightLab Imaging
HQ: United States
Website
- Description: Provider of optical coherence tomography (OCT) solutions for coronary imaging applications, including the M2x silo for data capture, display, processing, and storage; ImageWire and Helios occlusion balloon catheters for imaging of coronary atherosclerotic plaques; and C7-XR imaging systems and C7 Dragonfly imaging.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LightLab Imaging company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CorFlow Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CorFlow Therapeutics
2.2 - Growth funds investing in similar companies to CorFlow Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CorFlow Therapeutics
4.2 - Public trading comparable groups for CorFlow Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →